Anzeige
Mehr »
Login
Freitag, 29.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
NurExone Biologic: Technisches (täglich, wöchentlich, monatlich) & Analysten "Strong Buy"-Rating!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2H7XD | ISIN: US8106481059 | Ticker-Symbol: 2SX
Frankfurt
28.03.24
15:03 Uhr
4,600 Euro
+0,080
+1,77 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
SCPHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
SCPHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
4,5804,74028.03.
4,4804,84028.03.

Aktuelle News zur SCPHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
15.03.Earnings call: ScPharmaceuticals Q4 Revenue Jumps 61%, net loss at $13.8 million2
13.03.scPharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary1
13.03.scPharmaceuticals files for $200M mixed shelf offering2
13.03.scPharmaceuticals Inc. - S-8, Securities to be offered to employees in employee benefit plans-
13.03.Recap: scPharmaceuticals Q4 Earnings1
13.03.scPharmaceuticals Inc. - 10-K, Annual Report1
13.03.scPharmaceuticals GAAP EPS of -$0.35 beats by $0.07, revenue of $6.1M beats by $0.33M1
13.03.scPharmaceuticals Inc. - 8-K, Current Report1
13.03.scPharmaceuticals, Inc.: scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update61Generated 4Q 2023 net FUROSCIX® revenue of $6.1 million, at the upper end of the range provided in January and representing sequential growth of 61% from $3.8 million in 3Q 2023 Generated full-year...
► Artikel lesen
06.03.scPharmaceuticals, Inc.: scPharmaceuticals to Announce Fourth Quarter and Full-Year 2023 Financial Results on Wednesday, March 13, 20241
28.02.scPharmaceuticals, Inc.: scPharmaceuticals to Participate in Two Upcoming Investor Conferences1
05.01.scPharmaceuticals trades marginally higher on guiding revenue above consensus4
04.01.scPharmaceuticals Inc. - 8-K, Current Report1
04.01.scPharmaceuticals, Inc.: scPharmaceuticals Announces Preliminary Unaudited Q4 and Full-Year 2023 Net FUROSCIX Revenue197Company anticipates Q4 2023 net FUROSCIX revenue to be approximately $5.9 to $6.1 million; full-year net FUROSCIX revenue of approximately $13.4 to $13.6 million Gross-to-net (GTN) discount of approximately...
► Artikel lesen
09.11.23Earnings call: scPharmaceuticals Reports Strong Q3 2023, Optimistic about FUROSCIX's Future2
08.11.23Recap: scPharmaceuticals Q3 Earnings1
08.11.23scPharmaceuticals Inc. - 10-Q, Quarterly Report1
08.11.23scPharmaceuticals Inc. - 8-K, Current Report1
08.11.23scPharmaceuticals GAAP EPS of -$0.41 misses by $0.05, revenue of $3.8M beats by $0.38M1
08.11.23scPharmaceuticals, Inc.: scPharmaceuticals Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update124Generated net FUROSCIX® revenue of $3.8 million Ended Q3 2023 with cash, cash equivalents and short-term investments of $90.2 million Company to host investor conference call and webcast today, Wednesday...
► Artikel lesen
Seite:  Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1